Skip to main content
Top
Published in: Orphanet Journal of Rare Diseases 1/2022

Open Access 01-12-2022 | Porphyria Cutanea Tarda | Research

Porphyria cutanea tarda and patterns of long-term sick leave and disability pension: a 24-year nationwide matched-cohort study

Authors: Carl Michael Baravelli, Aasne Karine Aarsand, Sverre Sandberg, Mette Christophersen Tollånes

Published in: Orphanet Journal of Rare Diseases | Issue 1/2022

Login to get access

Abstract

Background

Porphyria cutanea tarda (PCT) is a skin disorder caused by a defect in the liver enzyme uroporphyrinogen decarboxylase and is associated with hepatitis C virus infection, high alcohol intake, smoking and iron overload. Data on the long-term morbidity of PCT is lacking.

Methods

We conducted a nationwide matched cohort study over a 24-year period. The study sample included 534 persons aged 18–67 years with a biochemically confirmed PCT diagnosis and a sample of 21,360 persons randomly selected from the working age population, matched on age, sex and educational attainment. We investigated if persons with sporadic and familial PCT had an increased risk of long-term sick leave (LTSL) or disability pension. We further assessed risk before (pre-PCT), during (during-PCT) and after (post-PCT) the typical period of first onset to diagnosis, treatment and remission.

Results

Overall, persons with PCT had a 40% increased risk (hazard ratio [HR] = 1.4, 95% confidence interval [CI] = 1.3, 1.5) of LTSL and a 50% increased risk (HR = 1.5, CI = 1.3, 1.7) of disability pension. Risk of disability pension was increased pre-PCT (HR = 1.3, CI 1.3 (1.0, 1.6), during-PCT (HR 1.5, CI 1.0, 2.2) and post-PCT (HR = 2.0, CI 1.5, 2.6). For LTSL, risk was increased pre-PCT (HR = 1.3, CI 1.1, 1.4) and during-PCT (HR = 1.5, CI 1.1, 2.1), but not post-PCT. Risk was greatest in persons with sporadic than familial PCT. Diagnostic reasons for disability pension that were increased compared to matched controls were PCT or skin disease in 11 of 199 cases (PCT: n = 7, incident rate ratios [IRR] = 49.2, CI = 38.8, 62.4; diseases of the skin and subcutaneous tissue, n = 4, IRR = 4.2, CI = 1.6, 11.0). The vast majority of diagnostic reasons for accessing disability pension were related to comorbidities, PCT susceptibility factors and more general health issues such as: malignant neoplasms (n = 12, IRR = 2.4, CI = 1.4, 4.2), substance and alcohol dependence (n = 7, IRR = 5.0, CI = 2.5, 10.1), neurotic and mood—disorders (n = 21, IRR = 1.7, CI = 1.1, 2.6), and diseases of the musculoskeletal system and connective tissue (n = 71, IRR = 2.5, CI = 1.9, 3.2).

Conclusions

Persons with PCT have an increased risk of LTSL and disability pension indicating significant morbidity in this patient group. Appropriate long-term follow-up and monitoring for relapses and co-morbid diseases are recommended.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Fontanellas A, Martinez-Fresno M, Garrido-Astray MC, Perucho T, Moran-Jimenez MJ, Garcia-Bravo M, et al. Smoking but not homozygosity for CYP1A2 g-163A allelic variant leads to earlier disease onset in patients with sporadic porphyria cutanea tarda. Exp Dermatol. 2010;19(8):e326–8.CrossRef Fontanellas A, Martinez-Fresno M, Garrido-Astray MC, Perucho T, Moran-Jimenez MJ, Garcia-Bravo M, et al. Smoking but not homozygosity for CYP1A2 g-163A allelic variant leads to earlier disease onset in patients with sporadic porphyria cutanea tarda. Exp Dermatol. 2010;19(8):e326–8.CrossRef
3.
go back to reference Aarsand AK, Boman H, Sandberg S. Familial and sporadic porphyria cutanea tarda: characterization and diagnostic strategies. Clin Chem. 2009;55(4):795–803.CrossRef Aarsand AK, Boman H, Sandberg S. Familial and sporadic porphyria cutanea tarda: characterization and diagnostic strategies. Clin Chem. 2009;55(4):795–803.CrossRef
4.
go back to reference Elder G. Porphyria: genetics—encyclopedia of life sciences (ELS). Chichester: Wiley; 2010. Elder G. Porphyria: genetics—encyclopedia of life sciences (ELS). Chichester: Wiley; 2010.
5.
go back to reference Elder GH. Alcohol intake and porphyria cutanea tarda. Clin Dermatol. 1999;17(4):431–6.CrossRef Elder GH. Alcohol intake and porphyria cutanea tarda. Clin Dermatol. 1999;17(4):431–6.CrossRef
6.
go back to reference Fargion S, Fracanzani AL. Prevalence of hepatitis C virus infection in porphyria cutanea tarda. J Hepatol. 2003;39(4):635–8.CrossRef Fargion S, Fracanzani AL. Prevalence of hepatitis C virus infection in porphyria cutanea tarda. J Hepatol. 2003;39(4):635–8.CrossRef
7.
go back to reference Rossmann-Ringdahl I, Olsson R. Porphyria cutanea tarda in a Swedish population: risk factors and complications. Acta Derm Venereol. 2005;85(4):337–41.CrossRef Rossmann-Ringdahl I, Olsson R. Porphyria cutanea tarda in a Swedish population: risk factors and complications. Acta Derm Venereol. 2005;85(4):337–41.CrossRef
8.
go back to reference Sampietro M, Fiorelli G, Fargion S. Iron overload in porphyria cutanea tarda. Haematologica. 1999;84(3):248–53.PubMed Sampietro M, Fiorelli G, Fargion S. Iron overload in porphyria cutanea tarda. Haematologica. 1999;84(3):248–53.PubMed
9.
go back to reference Badminton MN, Elder GH. Management of acute and cutaneous porphyrias. Int J Clin Pract. 2002;56(4):272–8.PubMed Badminton MN, Elder GH. Management of acute and cutaneous porphyrias. Int J Clin Pract. 2002;56(4):272–8.PubMed
10.
go back to reference Harper P, Wahlin S. Treatment options in acute porphyria, porphyria cutanea tarda, and erythropoietic protoporphyria. Curr Treat Options Gastroenterol. 2007;10(6):444–55.CrossRef Harper P, Wahlin S. Treatment options in acute porphyria, porphyria cutanea tarda, and erythropoietic protoporphyria. Curr Treat Options Gastroenterol. 2007;10(6):444–55.CrossRef
11.
go back to reference Singal AK. Porphyria cutanea tarda: recent update. Mol Genet Metab. 2019;128:271.CrossRef Singal AK. Porphyria cutanea tarda: recent update. Mol Genet Metab. 2019;128:271.CrossRef
12.
go back to reference Salameh H, Sarairah H, Rizwan M, Kuo YF, Anderson KE, Singal AK. Relapse of porphyria cutanea tarda after treatment with phlebotomy or 4-aminoquinoline antimalarials: a meta-analysis. Br J Dermatol. 2018;179(6):1351–7.CrossRef Salameh H, Sarairah H, Rizwan M, Kuo YF, Anderson KE, Singal AK. Relapse of porphyria cutanea tarda after treatment with phlebotomy or 4-aminoquinoline antimalarials: a meta-analysis. Br J Dermatol. 2018;179(6):1351–7.CrossRef
13.
go back to reference Siersema PD, ten Kate FJ, Mulder PG, Wilson JH. Hepatocellular carcinoma in porphyria cutanea tarda: frequency and factors related to its occurrence. Liver. 1992;12(2):56–61.CrossRef Siersema PD, ten Kate FJ, Mulder PG, Wilson JH. Hepatocellular carcinoma in porphyria cutanea tarda: frequency and factors related to its occurrence. Liver. 1992;12(2):56–61.CrossRef
14.
go back to reference Gisbert JP, Garcia-Buey L, Alonso A, Rubio S, Hernandez A, Pajares JM, et al. Hepatocellular carcinoma risk in patients with porphyria cutanea tarda. Eur J Gastroenterol Hepatol. 2004;16(7):689–92.CrossRef Gisbert JP, Garcia-Buey L, Alonso A, Rubio S, Hernandez A, Pajares JM, et al. Hepatocellular carcinoma risk in patients with porphyria cutanea tarda. Eur J Gastroenterol Hepatol. 2004;16(7):689–92.CrossRef
15.
go back to reference Fracanzani AL, Taioli E, Sampietro M, Fatta E, Bertelli C, Fiorelli G, et al. Liver cancer risk is increased in patients with porphyria cutanea tarda in comparison to matched control patients with chronic liver disease. J Hepatol. 2001;35(4):498–503.CrossRef Fracanzani AL, Taioli E, Sampietro M, Fatta E, Bertelli C, Fiorelli G, et al. Liver cancer risk is increased in patients with porphyria cutanea tarda in comparison to matched control patients with chronic liver disease. J Hepatol. 2001;35(4):498–503.CrossRef
16.
go back to reference Linet MS, Gridley G, Nyren O, Mellemkjaer L, Olsen JH, Keehn S, et al. Primary liver cancer, other malignancies, and mortality risks following porphyria: a cohort study in Denmark and Sweden. Am J Epidemiol. 1999;149(11):1010–5.CrossRef Linet MS, Gridley G, Nyren O, Mellemkjaer L, Olsen JH, Keehn S, et al. Primary liver cancer, other malignancies, and mortality risks following porphyria: a cohort study in Denmark and Sweden. Am J Epidemiol. 1999;149(11):1010–5.CrossRef
17.
go back to reference Baravelli CM, Sandberg S, Aarsand AK, Tollanes MC. Porphyria cutanea tarda increases risk of hepatocellular carcinoma and premature death: a nationwide cohort study. Orphanet J Rare Dis. 2019;14(1):77.CrossRef Baravelli CM, Sandberg S, Aarsand AK, Tollanes MC. Porphyria cutanea tarda increases risk of hepatocellular carcinoma and premature death: a nationwide cohort study. Orphanet J Rare Dis. 2019;14(1):77.CrossRef
18.
go back to reference Munoz-Santos C, Guilabert A, Moreno N, Gimenez M, Darwich E, To-Figueras J, et al. The association between porphyria cutanea tarda and diabetes mellitus: analysis of a long-term follow-up cohort. Br J Dermatol. 2011;165(3):486–91.CrossRef Munoz-Santos C, Guilabert A, Moreno N, Gimenez M, Darwich E, To-Figueras J, et al. The association between porphyria cutanea tarda and diabetes mellitus: analysis of a long-term follow-up cohort. Br J Dermatol. 2011;165(3):486–91.CrossRef
19.
go back to reference OCED. Sickness, disability and work: breaking the barriers; 2010. OCED. Sickness, disability and work: breaking the barriers; 2010.
20.
go back to reference Andersen J, Nordin K, Sandberg S. Illness perception and psychological distress in persons with porphyria cutanea tarda. Acta Derm Venereol. 2016;96(5):674–8.CrossRef Andersen J, Nordin K, Sandberg S. Illness perception and psychological distress in persons with porphyria cutanea tarda. Acta Derm Venereol. 2016;96(5):674–8.CrossRef
28.
go back to reference Badminton M, Deacon A, Elder G. The porphyrias and other disorders of porphyrin metabolism. In: Burtis C, Aashwood E, Bruns D, editors. Tietz textbook of clinical chemistry and molecular diagnostics. St. Louis: Elsevier Saunders; 2012. p. 1031–52.CrossRef Badminton M, Deacon A, Elder G. The porphyrias and other disorders of porphyrin metabolism. In: Burtis C, Aashwood E, Bruns D, editors. Tietz textbook of clinical chemistry and molecular diagnostics. St. Louis: Elsevier Saunders; 2012. p. 1031–52.CrossRef
29.
go back to reference Long JS, Freese J. Regression models for categorical dependent variables using stata (Second Edition). Los Angeles: Stata Press; 2006. Long JS, Freese J. Regression models for categorical dependent variables using stata (Second Edition). Los Angeles: Stata Press; 2006.
30.
go back to reference Newcombe RG. Re: “confidence limits made easy: interval estimation using a substitution method.” Am J Epidemiol. 1999;149(9):884–5.CrossRef Newcombe RG. Re: “confidence limits made easy: interval estimation using a substitution method.” Am J Epidemiol. 1999;149(9):884–5.CrossRef
Metadata
Title
Porphyria cutanea tarda and patterns of long-term sick leave and disability pension: a 24-year nationwide matched-cohort study
Authors
Carl Michael Baravelli
Aasne Karine Aarsand
Sverre Sandberg
Mette Christophersen Tollånes
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2022
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-022-02201-3

Other articles of this Issue 1/2022

Orphanet Journal of Rare Diseases 1/2022 Go to the issue